Friday, 6 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 15, 2026

Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu

View original at globenewswire.com
Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu MAINZ, Deutschland, 15…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Readers are advised to review Risk Factors in BioNTech's Form 6-K report for the period ending March 31, 2026, and subsequent SEC filings.

    60% confidence

  • Forward-looking statements in this press release are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

    60% confidence

  • BioNTech is intensifying its focus on its growing late-stage oncology pipeline while continuing early research and development aimed at long-term innovations.

    60% confidence

  • BioNTech aims to sustainably improve treatment options for people with cancer and develop innovative drugs with tumor-cross-cutting or synergistic potential to address cancer across all stages of the disease.

    60% confidence

Data points we hold from this source

BioNTech SE · supervisory board size8 members
BioNTech SE · shareholder attendance92 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com